Results 31 to 40 of about 1,093,493 (290)

Janus kinase inhibitors in autoimmune diseases [PDF]

Annals of the Rheumatic Diseases, 2013
Biological therapies directed at proinflammatory cytokines have irrevocably changed the landscape of treatment of rheumatoid arthritis (RA) and other autoimmune diseases. With the advances in our knowledge in cytokine signalling, the question emerges whether targeting intracellular signalling might also be a safe and efficacious strategy. Janus kinases
John J, O'Shea, Apostolos, Kontzias, Kunihiro, Yamaoka, Yoshiya, Tanaka, Arian, Laurence   +4 more
openaire   +2 more sources

Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis

Acta Dermato-Venereologica, 2023
The aim of this study was to compare the efficacy and safety of treatment with Janus kinase inhibitors for alopecia areata, measured by change in Severity of Alopecia Tool (SALT) score.
Farnam Barati Sedeh, Thorunn Elísabet Michaelsdóttir, Mattias Arvid Simon Henning, Gregor Borut Ernst Jemec, Kristina Sophie Ibler   +4 more
doaj   +1 more source

Tofacitinib successful treatment of idiopathic twenty-nail dystrophy: a case report

Journal of Dermatological Treatment
Purpose Twenty-nail dystrophy (TND) is a chronic nail disorder affecting all or some nails and posing a significant therapeutic challenge for dermatologists.
Wenjun Zhao, Shijun Shan, Dongmei Liu
doaj   +1 more source

Comparative Safety of Janus Kinase Inhibitors Versus Tumor Necrosis Factor Inhibitors: A Nationwide Cohort Study

, 2023
This retrospective cohort study aims to compare the risk of three-point major adverse events, malignancy, and serious infection between Janus kinase inhibitors and tumor necrosis factor inhibitors by using nationwide claims data of ...
Dongwon Yoon, Minkyo Song, Ju-Young Shin, Yongtai Cho, Farzin Khosrow-Khavar   +4 more
core   +1 more source

Metastatic niche shaped by host factors influences disseminated cancer cell fate

FEBS Letters, EarlyView.
Metastasis is shaped not only by cancer cells but also by the environments they encounter. This review explores how factors such as aging, diet, the microbiome, lifestyle, and environmental exposures remodel organ‐specific niches in the lung, liver, bone, and brain, influencing where metastatic cells survive, remain dormant, or grow, and ultimately ...
Gwennan Delyth Ward, Álvaro Ruiz‐Tabas, Patricia Altea‐Manzano   +2 more
wiley   +1 more source

Trisubstituted pyrazolopyrimidines as novel angiogenesis inhibitors. [PDF]

, 2013
Current inhibitors of angiogenesis comprise either therapeutic antibodies (e.g. bevacicumab binding to VEGF-A) or small molecular inhibitors of receptor tyrosin kinases like e.g. sunitinib, which inhibits PDGFR and VEGFR.
Gucký, Tomáš, Stefan Zahler, Krystof, Vladimir, Strnad, Miroslav, Liebl, Johanna, Vollmar, Angelika M., Fürst, Robert, Vladimir Krystof, Robert Fürst, Sabine B Weitensteiner, Miroslav Strnad, Johanna Liebl, Havlíček, Libor, Tomáš Gucký, Weitensteiner, Sabine B., Zahler, Stefan, Libor Havlíček, Angelika M Vollmar   +17 more
core   +2 more sources

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician

Journal of Family Medicine and Primary Care
Guidelines for primary care clinicians on monitoring and safety guidelines regarding Janus kinase and tyrosine kinase 2 inhibitors in the treatment of inflammatory skin conditions are often unclear.
Abigail Beard, Shannon C. Trotter
doaj   +1 more source

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I [PDF]

, 2012
Background: Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (Ph + ALL) are caused by the t(9;22), which fuses BCR to ABL resulting in deregulated ABL-tyrosine kinase activity.
Ruimi, Nili, Martin Ruthardt, Mahajna, Jamal, Khateb, Mamduh, Jamal Mahajna, Ruthardt, Martin, Ottmann, Oliver G., Oliver Gerhard Ottmann, Mian, Afsar Ali, Nili Ruimi, Yousef Najajreh, Afsar Ali Mian, Ottmann, Oliver Gerhard, Susanne Badura, Metodieva, Anna, Najajreh, Yousef, Anna Metodieva, Mamduh Khateb, Badura, Susanne   +18 more
core   +2 more sources

Janus Kinase Inhibitors - A next generation treatment in Dermatology

, 2022
Over the past few decades, drugs targeting cytokines and their receptors have been researched and developed. These agents act on molecular targets at the subcellular level.
Sadaf Ibrahim, Muhammad Nadeem, Nadia Ali Azfar   +2 more
core   +1 more source